• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-world Short-term Effectiveness of Ustekinumab in Crohn's Disease: Results from a Multicenter, Prospective Study in China.

作者信息

Cao Qian, Chen Chunxiao, Gao Xiang, Chen Yan, Hu Naizhong, Liang Jie, Wu Kaichun

机构信息

Department of Gastroenterology, Sir Run Run Shaw Hospital, College of Medicine Zhejiang University, Hangzhou, China.

Department of Gastroenterology, The First Affiliated Hospital, College of Medicine Zhejiang University, Hangzhou, China.

出版信息

Inflamm Bowel Dis. 2022 Jun 2;28(Suppl 2):S42-S44. doi: 10.1093/ibd/izac078.

DOI:10.1093/ibd/izac078
PMID:35442448
Abstract
摘要

相似文献

1
Real-world Short-term Effectiveness of Ustekinumab in Crohn's Disease: Results from a Multicenter, Prospective Study in China.乌司奴单抗在中国克罗恩病中的真实世界短期疗效：一项多中心前瞻性研究结果
Inflamm Bowel Dis. 2022 Jun 2;28(Suppl 2):S42-S44. doi: 10.1093/ibd/izac078.
2
Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn's disease: a real-world multicenter Brazilian study.在克罗恩病生物初治和生物经验丰富的抗肿瘤坏死因子患者中乌司奴单抗的长期疗效和安全性：一项真实世界的多中心巴西研究。
BMC Gastroenterol. 2022 Apr 21;22(1):199. doi: 10.1186/s12876-022-02280-3.
3
Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-naïve Versus Bio-experienced Patients With Crohn's Disease: Real-world Experience From a Large Canadian Center.在克罗恩病生物初治与生物经验患者中乌司奴单抗的临床、内镜和放射学疗效：来自加拿大一大型中心的真实世界经验。
Inflamm Bowel Dis. 2023 Jun 1;29(6):866-874. doi: 10.1093/ibd/izac149.
4
The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab.抗 TNF 药物和 vedolizumab 或 ustekinumab 均治疗无效的克罗恩病患者的结局。
Dig Liver Dis. 2020 Oct;52(10):1148-1155. doi: 10.1016/j.dld.2020.07.031. Epub 2020 Aug 20.
5
Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.130 例抗 TNF 治疗失败的克罗恩病患者中乌司奴单抗或维得利珠单抗治疗 1 年后的疗效比较。
Aliment Pharmacol Ther. 2020 Oct;52(8):1341-1352. doi: 10.1111/apt.16057. Epub 2020 Sep 10.
6
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.乌司奴单抗相较于维得利珠单抗在既往抗 TNF 治疗失败的克罗恩病患者中具有更优的有效性结局。
Aliment Pharmacol Ther. 2020 Jul;52(1):123-134. doi: 10.1111/apt.15745. Epub 2020 May 22.
7
Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.比较乌司奴单抗和维得利珠单抗治疗对肿瘤坏死因子治疗应答不佳的克罗恩病患者的短期和长期疗效。
Aliment Pharmacol Ther. 2021 Jun;53(12):1289-1299. doi: 10.1111/apt.16377. Epub 2021 Apr 28.
8
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.乌司奴单抗诱导和维持治疗克罗恩病。
N Engl J Med. 2016 Nov 17;375(20):1946-1960. doi: 10.1056/NEJMoa1602773.
9
Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.用于维持克罗恩病缓解的抗IL-12/23 p40抗体
Cochrane Database Syst Rev. 2019 Dec 12;12(12):CD012804. doi: 10.1002/14651858.CD012804.pub2.
10
Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study.基于倾向评分调整的乌司奴单抗与抗 TNF 在克罗恩病中真实世界疗效比较：前瞻性、观察性 RUN-CD 研究诱导期结果。
Inflamm Bowel Dis. 2023 Nov 2;29(11):1741-1750. doi: 10.1093/ibd/izac271.

引用本文的文献

1
Short-Term Effectiveness of Ustekinumab in Crohn's Disease: Results from a Real-World Retrospective Multicenter Study in China.乌司奴单抗治疗克罗恩病的短期疗效：一项中国真实世界回顾性多中心研究的结果
Int J Gen Med. 2025 May 20;18:2589-2597. doi: 10.2147/IJGM.S520984. eCollection 2025.
2
New Interleukin-23 Antagonists' Use in Crohn's Disease.新型白细胞介素-23拮抗剂在克罗恩病中的应用。
Pharmaceuticals (Basel). 2025 Mar 22;18(4):447. doi: 10.3390/ph18040447.
3
Intestinal mRNA expression profiles associated with mucosal healing in ustekinumab-treated Crohn's disease patients: bioinformatics analysis and prospective cohort validation.
与乌司奴单抗治疗的克罗恩病患者黏膜愈合相关的肠道 mRNA 表达谱：生物信息学分析和前瞻性队列验证。
J Transl Med. 2024 Jun 26;22(1):595. doi: 10.1186/s12967-024-05427-w.
4
A bibliometric and visual analysis of the use of ustekinumab in Crohn's disease using CiteSpace.使用CiteSpace对乌司奴单抗在克罗恩病中的应用进行文献计量学和可视化分析。
Front Pharmacol. 2024 Jan 10;14:1322319. doi: 10.3389/fphar.2023.1322319. eCollection 2023.
5
Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn's disease.额外静脉注射优特克单抗再诱导治疗是难治性克罗恩病患者的一种有效优化策略。
Front Med (Lausanne). 2023 Jul 24;10:1105981. doi: 10.3389/fmed.2023.1105981. eCollection 2023.
6
Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial.乌司奴单抗改善中重度克罗恩病患者的健康相关生活质量：STARDUST 试验第 104 周的结果。
United European Gastroenterol J. 2023 Jun;11(5):410-422. doi: 10.1002/ueg2.12384. Epub 2023 May 4.